Last reviewed · How we verify
Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding (BAIT)
This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed. Red blood cell transfusions are part of the standard of care for patients with leukemia. This study evaluates two transfusion strategies: one that maintains hemoglobin levels above the standard-of-care threshold, reflecting current routine practice; and another that maintains hemoglobin levels above 110 g/L, which is closer to the normal hemoglobin range. The normal hemoglobin range is 120-160 g/L for females and 140-180 g/L for males. Raising hemoglobin levels closer to normal values may reduce bleeding risk.
Details
| Lead sponsor | Donald Arnold |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 60 |
| Start date | Fri Apr 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Nov 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Acute Leukemia
- Acute Myeloid Leukemia (AML)
- Acute Lymphocytic Leukaemia
Interventions
- RBC transfusion strategy
Countries
Canada